BridgeBio Oncology Therapeutics, Inc. Accrued Liabilities, Current
BridgeBio Oncology Therapeutics, Inc. (BBOT) had Accrued Liabilities, Current of $1.78 million as of 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2025-05-15
- 2025-03-31: Accrued Liabilities, Current $1.78M.
- 2024-12-31: Accrued Liabilities, Current $119.71K.
- 2024-09-30: Accrued Liabilities, Current $126.69K.
- 2024-06-30: Accrued Liabilities, Current $79.14K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2025-03-31 | $1.78M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $119.71K 10-Q · filed 2025-05-15 |
| 2024-09-30 | $126.69K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $79.14K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $23.33K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $15.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |